Edgewise Therapeutics (EWTX) Competitors $13.15 -0.43 (-3.14%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. QGEN, ROIV, SRPT, RVMD, LNTH, TGTX, LEGN, BBIO, AXSM, and TLXShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Qiagen (QGEN), Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Qiagen Roivant Sciences Sarepta Therapeutics Revolution Medicines Lantheus TG Therapeutics Legend Biotech BridgeBio Pharma Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Qiagen (NYSE:QGEN) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation. Do insiders & institutionals have more ownership in QGEN or EWTX? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 24.1% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer QGEN or EWTX? Qiagen presently has a consensus target price of $47.71, suggesting a potential upside of 18.08%. Edgewise Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 197.31%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community favor QGEN or EWTX? Qiagen received 211 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 71.70% of users gave Edgewise Therapeutics an outperform vote while only 60.29% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.29% Underperform Votes16439.71% Edgewise TherapeuticsOutperform Votes3871.70% Underperform Votes1528.30% Is QGEN or EWTX more profitable? Qiagen has a net margin of 4.23% compared to Edgewise Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.92% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% Edgewise Therapeutics N/A -26.83%-25.67% Which has stronger valuation & earnings, QGEN or EWTX? Qiagen has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B4.54$83.59M$0.36112.23Edgewise TherapeuticsN/AN/A-$100.16M-$1.45-9.37 Which has more risk & volatility, QGEN or EWTX? Qiagen has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Does the media prefer QGEN or EWTX? In the previous week, Edgewise Therapeutics had 7 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 12 mentions for Qiagen. Qiagen's average media sentiment score of 0.45 beat Edgewise Therapeutics' score of 0.20 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryQiagen beats Edgewise Therapeutics on 11 of the 17 factors compared between the two stocks. Remove Ads Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-9.056.9923.2518.07Price / SalesN/A198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book3.005.926.493.99Net Income-$100.16M$142.37M$3.21B$247.18M7 Day Performance-42.06%-9.32%-6.42%-6.42%1 Month Performance-46.81%-10.26%-0.68%-7.44%1 Year Performance-26.59%-15.08%6.05%-4.31% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics1.8262 of 5 stars$13.15-3.1%$40.38+207.0%-26.6%$1.25BN/A-8.7660Analyst ForecastOptions VolumeNews CoverageGap DownQGENQiagen3.4911 of 5 stars$39.87+0.5%$47.71+19.7%-0.9%$8.85B$1.98B111.026,030Gap UpROIVRoivant Sciences2.3426 of 5 stars$10.83+0.4%$18.08+67.0%-13.0%$7.73B$122.59M-72.20860SRPTSarepta Therapeutics4.7905 of 5 stars$76.33+3.0%$167.41+119.3%-53.8%$7.41B$1.90B61.061,314Quiet Period ExpirationNews CoverageGap UpRVMDRevolution Medicines4.1268 of 5 stars$39.34+3.2%$66.31+68.6%+4.7%$7.31B$742,000.00-10.96250Analyst ForecastNews CoveragePositive NewsGap DownLNTHLantheus4.3254 of 5 stars$99.44+1.8%$129.43+30.2%+64.2%$6.81B$1.53B16.55700Positive NewsGap DownTGTXTG Therapeutics2.8877 of 5 stars$42.61-0.9%$40.67-4.6%+171.9%$6.69B$329.00M-426.06290Positive NewsGap DownLEGNLegend Biotech2.5849 of 5 stars$36.33-1.7%$79.00+117.5%-41.7%$6.67B$627.24M-38.241,800Short Interest ↓News CoveragePositive NewsGap DownBBIOBridgeBio Pharma4.5869 of 5 stars$37.22+7.0%$52.90+42.1%+16.6%$6.61B$221.90M-13.06400Insider TradeGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.6661 of 5 stars$129.17+1.9%$167.36+29.6%+46.8%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/APositive News Remove Ads Related Companies and Tools Related Companies Qiagen Competitors Roivant Sciences Competitors Sarepta Therapeutics Competitors Revolution Medicines Competitors Lantheus Competitors TG Therapeutics Competitors Legend Biotech Competitors BridgeBio Pharma Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EWTX Stock Free EWTX Stock Alerts